EP3600393A4 - Kombinationstherapie zur behandlung von soliden und hämatologischen bösartigen tumoren - Google Patents
Kombinationstherapie zur behandlung von soliden und hämatologischen bösartigen tumoren Download PDFInfo
- Publication number
- EP3600393A4 EP3600393A4 EP18771103.1A EP18771103A EP3600393A4 EP 3600393 A4 EP3600393 A4 EP 3600393A4 EP 18771103 A EP18771103 A EP 18771103A EP 3600393 A4 EP3600393 A4 EP 3600393A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- solid
- treatment
- combination therapy
- hematological cancers
- hematological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 230000002489 hematologic effect Effects 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762475032P | 2017-03-22 | 2017-03-22 | |
US201762475036P | 2017-03-22 | 2017-03-22 | |
US15/871,802 US20180142019A1 (en) | 2016-10-21 | 2018-01-15 | Therapeutic cd47 antibodies |
PCT/US2018/023860 WO2018175790A1 (en) | 2017-03-22 | 2018-03-22 | Combination therapy for the treatment of solid and hematological cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3600393A1 EP3600393A1 (de) | 2020-02-05 |
EP3600393A4 true EP3600393A4 (de) | 2020-12-23 |
Family
ID=63585757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18771103.1A Withdrawn EP3600393A4 (de) | 2017-03-22 | 2018-03-22 | Kombinationstherapie zur behandlung von soliden und hämatologischen bösartigen tumoren |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3600393A4 (de) |
JP (1) | JP7170331B2 (de) |
CN (1) | CN111148535A (de) |
AU (1) | AU2018240377A1 (de) |
CA (1) | CA3057139A1 (de) |
SG (1) | SG11201908602UA (de) |
WO (1) | WO2018175790A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2015122228A (ru) | 2012-12-12 | 2017-01-19 | Васкулокс Инк. | Терапевтические антитела к CD47 |
US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
RU2748401C2 (ru) | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
EP3892637A1 (de) * | 2018-12-03 | 2021-10-13 | Shanghai Pharmaexplorer Co., Ltd. | Cd47-antikörper, verfahren zu seiner herstellung und seine verwendungen |
EP3969120A4 (de) * | 2019-05-16 | 2023-09-13 | Arch Oncology, Inc. | Therapeutische zusammensetzungen und verfahren zur behandlung von krebs in kombination mit analoga von interleukinproteinen |
JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてcd47に結合する薬物の干渉を低減するための方法及び試薬 |
CN114901364A (zh) * | 2019-10-23 | 2022-08-12 | 安驰肿瘤公司 | 用于治疗实体癌和血液癌的组合疗法 |
JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Cd47、pd-l1に特異的な抗体、およびその使用 |
WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040073013A1 (en) * | 1999-03-10 | 2004-04-15 | Naoshi Fukushima | Polypeptide inducing apoptosis |
WO2014123580A1 (en) * | 2013-02-06 | 2014-08-14 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
WO2017049251A2 (en) * | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101719B2 (en) * | 2003-11-11 | 2012-01-24 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-CD47 antibody |
RU2531758C2 (ru) * | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
WO2011091286A1 (en) * | 2010-01-21 | 2011-07-28 | Immunogen, Inc. | Compositions and methods for treatment of ovarian cancer |
NZ628314A (en) * | 2012-02-06 | 2017-01-27 | Inhibrx Lp | Cd47 antibodies and methods of use thereof |
MX2014015830A (es) * | 2012-06-21 | 2015-03-05 | Compugen Ltd | Anticuerpos lsr y usos de los mismos para el tratamiento de cancer. |
US9221908B2 (en) * | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
-
2018
- 2018-03-22 EP EP18771103.1A patent/EP3600393A4/de not_active Withdrawn
- 2018-03-22 WO PCT/US2018/023860 patent/WO2018175790A1/en unknown
- 2018-03-22 JP JP2019551449A patent/JP7170331B2/ja active Active
- 2018-03-22 AU AU2018240377A patent/AU2018240377A1/en not_active Abandoned
- 2018-03-22 SG SG11201908602U patent/SG11201908602UA/en unknown
- 2018-03-22 CA CA3057139A patent/CA3057139A1/en active Pending
- 2018-03-22 CN CN201880028490.2A patent/CN111148535A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040073013A1 (en) * | 1999-03-10 | 2004-04-15 | Naoshi Fukushima | Polypeptide inducing apoptosis |
WO2014123580A1 (en) * | 2013-02-06 | 2014-08-14 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
WO2017049251A2 (en) * | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
Non-Patent Citations (8)
Title |
---|
ANA-CAROLINA MARTINEZ-TORRES ET AL: "CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLC[gamma]1 Activation: Evidence from Mice and Humans", PLOS MEDICINE, vol. 12, no. 3, 3 March 2015 (2015-03-03), pages e1001796, XP055318218, DOI: 10.1371/journal.pmed.1001796 * |
JESSICA LO ET AL: "Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma", LIVER INTERNATIONAL, vol. 36, no. 5, 1 May 2016 (2016-05-01), GB, pages 737 - 745, XP055505901, ISSN: 1478-3223, DOI: 10.1111/liv.12963 * |
KATHAWALA: "Abstract 4001: The anti-CD47 antibody Hu5F9-G4 activates macrophages and inhibits ovarian cancer xenografts, alone and in combination with chemotherapy or immunotherapy | Cancer Research", AACR 107TH ANNUAL MEETING 2016, vol. 76, 15 July 2016 (2016-07-15), XP055506116, DOI: 10.1158/1538-7445.AM2016-4001 * |
PARTHA MANNA ET AL: "CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.", CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 1026 - 1036, XP055030076, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-03-1708 * |
PER-ARNE OLDENBORG: "CD47: A cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease", ISRN HEMATOLOGY, 1 January 2013 (2013-01-01), pages 1 - 19, XP055663144, DOI: 10.1155/2013/614619 * |
ROBERT W KARR: "Experimental data on anti-CD47 antibodies", OPPOSITION PROCEEDINGS RELATING TO EUROPEAN PATENT EP2242512, 20 January 2017 (2017-01-20), pages 1 - 11, XP055692350, Retrieved from the Internet <URL:https://register.epo.org/application?number=EP09701993&lng=en&tab=doclist> [retrieved on 20200506] * |
See also references of WO2018175790A1 * |
XIAOJUAN LIU ET AL: "CD47 blockade triggers T cell-mediated destruction of immunogenic tumors", NATURE MEDICINE, vol. 21, no. 10, 31 October 2015 (2015-10-31), New York, pages 1209 - 1215, XP055478072, ISSN: 1078-8956, DOI: 10.1038/nm.3931 * |
Also Published As
Publication number | Publication date |
---|---|
JP2020511481A (ja) | 2020-04-16 |
EP3600393A1 (de) | 2020-02-05 |
JP7170331B2 (ja) | 2022-11-14 |
WO2018175790A1 (en) | 2018-09-27 |
CN111148535A (zh) | 2020-05-12 |
CA3057139A1 (en) | 2018-09-27 |
AU2018240377A1 (en) | 2019-10-31 |
SG11201908602UA (en) | 2019-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3600393A4 (de) | Kombinationstherapie zur behandlung von soliden und hämatologischen bösartigen tumoren | |
EP3600281A4 (de) | Kombinationstherapie zur behandlung oder prävention von tumoren | |
EP3490581A4 (de) | Neuromodulierende zusammensetzungen und zugehörige therapeutische verfahren zur behandlung von krebs | |
EP3325473A4 (de) | Verbindungen und verwendungen davon in der behandlung von krebs und anderen medizinischen störungen | |
EP3585389A4 (de) | Behandlung von egfr-vermitteltem krebs mit weniger nebenwirkungen | |
EP3894392A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
EP3565558A4 (de) | Kombinationstherapie zur behandlung von krebs | |
EP3307240A4 (de) | Kombinationstherapie zur krebsbehandlung | |
EP3580560A4 (de) | Verfahren zur erkennung und behandlung von lungenkrebs | |
EP3359192A4 (de) | Kombinationstherapie zur krebsbehandlung | |
ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
IL274837B1 (en) | Combined treatment for cancer | |
EP3615056A4 (de) | Verfahren und mittel zur erkennung und behandlung von krebs | |
EP3558279A4 (de) | Zusammensetzungen und verfahren zur behandlung chronischer schmerzen | |
EP3490561A4 (de) | Kombinationen zur behandlung von krebs | |
EP3503887A4 (de) | Kombinationen zur behandlung von krebs | |
EP4048406A4 (de) | Kombinationstherapie zur behandlung von soliden und hämatologischen bösartigen tumoren | |
EP3478284A4 (de) | Verbindungen und zusammensetzungen zur behandlung von krebs | |
EP3402527A4 (de) | Therapeutische nanopartikel zur behandlung von neuroblastom und anderen krebsarten | |
EP3820492A4 (de) | Apmv und ihre verwendungen zur behandlung von krebs | |
IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
IL266993A (en) | Combined therapy for cancer treatment | |
EP3860610A4 (de) | Kombinationstherapie zur behandlung von krebs | |
EP3897650A4 (de) | Kombinationstherapie zur behandlung von krebs | |
IL272147A (en) | Methods and preparations for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190920 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0039000000 Ipc: C07K0016280000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201125 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101ALI20201119BHEP Ipc: A61K 35/28 20150101ALI20201119BHEP Ipc: C07K 16/28 20060101AFI20201119BHEP Ipc: C12N 5/0786 20100101ALI20201119BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230503 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230705 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231116 |